Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

1. Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.Arthritis & rheumatology (Hoboken, N.J.) · 2021
   Article
2. N-TproBNP as biomarker in systemic sclerosis.Clinical reviews in allergy & immunology · 2012
   Review
3. Systemic sclerosis and the heart: current diagnosis and management.Current opinion in rheumatology · 2011
   Review

Corrections and comments

• Comment on
  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.2008

Authors and funding

4 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as